At Avestria Ventures, we invest in early-stage women’s health and female- led life science ventures — and we still hear that these areas represent a “niche market” and/or, if they were truly lucrative, someone would have already invested in them.
But how can female founders and women’s health startups be dismissed when neither group has received equal funding or attention as male founders, male-led ventures, and even men’s healthcare? These International Women’s Day, we’re looking at the numbers behind female entrepreneurship, women in venture capital, and women’s healthcare.
The Numbers Behind Female Founders:
Firstly, about 2.3% of venture capital dollars went to female founders in…
Why Avestria Invested in this Clinical Research Platform
In this series, we explain why we invested in our current portfolio companies. In the process, we hope to highlight the white spaces in women’s health and the life sciences — as well as the people, products, and companies working to fill those gaps. The name “Under the Microscope” refers both to our extensive due diligence process and our investment focus on healthcare and the life sciences.
When individuals use a healthcare product, they’re assuming the product will work safely and effectively. For white men, those assumptions are usually a reality.
The ethnic makeup of participants in clinical trials, which…
Why Avestria Invested in this Nasal Swab Collection-Focused Startup
In this series, we explain why we invested in our current portfolio companies. In the process, we hope to highlight the white spaces in women’s health and the life sciences — as well as the people, products, and companies working to fill those gaps. The name “Under the Microscope” refers both to our extensive due diligence process and our investment focus on healthcare and the life sciences.
In December, the New York Times ran a feature: “Nobody Sees Us: Testing Lab Workers Strain Under the Demand.” …
Why Avestria Invested in this UTI-Focused Startup
In this series, we explain why we invested in our current portfolio companies. In the process, we hope to highlight the white spaces in women’s health and the life sciences — as well as the people, products, and companies working to fill those gaps. The name “Under the Microscope” refers both to our extensive due diligence process and our investment focus on healthcare and the life sciences.
“I’ve been there — stuck in the awful cycle of UTIs. In 2014, I had 8 UTIs,” Uqora’s Co-Founder and CEO Jenna Ryan writes on Uqora’s “Our Story” webpage.
Why Avestria Invested in this Genetic Health Startup
In this series, we explain why we invested in our current portfolio companies. In the process, we hope to highlight the white spaces in women’s health and the life sciences — as well as the people, products, and companies working to fill those gaps. The name “Under the Microscope” refers both to our extensive due diligence process and our investment focus on healthcare and the life sciences.
On February 12, 2020, at the UN Headquarters in New York City, Lisa Alderson addressed the United Nations General Assembly at the 5th International Day of Women and Girls in Science Assembly. Lisa…
Why Avestria Invested in this Physician Education Startup
In this series, we explain why we invested in our current portfolio companies. In the process, we hope to highlight the white spaces in women’s health and the life sciences — as well as the people, products, and companies working to fill those gaps. The name “Under the Microscope” refers both to our extensive due diligence process and our investment focus on healthcare and the life sciences.
Medical information doubles every 73 days. That doubling time has only increased in recent years: from 50 years in 1950, to 7 years in 1980, and down to 3.5 years in 2010. To…
Why Avestria Invested in this Fetal Heath-Focused Startup
In this series, we explain why we invested in our current portfolio companies. In the process, we hope to highlight the white spaces in women’s health and the life sciences — as well as the people, products, and companies working to fill those gaps. The name “Under the Microscope” refers both to our extensive due diligence process and our investment focus on healthcare and the life sciences.
In December, the U.S Department of Health and Human Services outlined its maternal health goals for the next few years: reducing maternal mortality rate by 50%, reducing low-risk Cesarean delivery rate by 25%…
Why Avestria Invested in this Vaginal Dryness-Focused Startup
In this series, we explain why we invested in our current portfolio companies. In the process, we hope to highlight the white spaces in women’s health and the life sciences — as well as the people, products, and companies working to fill those gaps. The name “Under the Microscope” refers both to our extensive due diligence process and our investment focus on healthcare and the life sciences.
1.3 million women become menopausal every year — and that number is only going to grow. A 2015 study estimates that 1.2 billion women across the world will be menopausal or post-menopausal by…
Why Avestria Invested in this PPH-Focused Startup
Update: On March 29, 2021, Merck announced it was going to acquire Alydia Health, on behalf of its planned spinoff, Organon, for up to $240M. Congrats, Alydia!
In this series, we explain why we invested in our current portfolio companies. In the process, we hope to highlight the white spaces in women’s health and the life sciences — as well as the people, products, and companies working to fill those gaps. The name “Under the Microscope” refers both to our extensive due diligence process and our investment focus on healthcare and the life sciences.
Avestria Ventures
Investing in early-stage women’s health and female-led life sciences companies.
